Protara reports positive Phase 1a data for TARA-002 in NMIBC; plans Phase 2 trial in 2H2023

Protara Therapeutics, Inc.

TARA-002 well tolerated at all three doses; no dose-limiting toxicities; 40KE dose selected for further trials.
Of 3 evaluable CIS patients, 1 heavily pre-treated BCG-unresponsive patient achieved complete response; tumor regression in other 2.
ADVANCED-2 Phase 1b/2 trial to enroll up to 102 CIS patients (BCG-naïve and BCG-unresponsive) starting 2H2023.
Company expects current resources to fund operations into 2025, supporting clinical plans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.